// Account brief

AbbVie

Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source. The brief covers the whole of AbbVie. Allergan Aesthetics R&D is included only where it is drug discovery, and its commercial and manufacturing activity is out of scope.

Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.

Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.

Scores

Theme Priority (1 to 10) Delivery (0 to 10) Stage Commitments made public, last 12 months R&D roles open on 6 Oct 2026
AI in drug discovery 5 2 funded or contracted 3 6
Research labs and data 3 4 live 0 9

The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.

Summary

AbbVie names AI among its R&D areas of innovation and says it uses AI and machine learning across its pipeline, from molecule property prediction to target identification. AI in drug discovery scores 5 out of 10 for priority and 2 for delivery: delivery rests on the funded Iambic collaboration, and AbbVie's internal AI use is claimed, with no identifiable system in operation shown. Research labs and data scores 3 for priority and 4 for delivery, because AbbVie describes a live unified knowledge platform, ARCH, that connects data from more than 170 internal and external sources. In the last 12 months AbbVie made three AI commitments public, all in September 2026: the Iambic collaboration and two federated AI model initiatives with other pharma companies, against two in the year before; we identified no research labs and data commitment in either year. On 6 October 2026 it had 6 open R&D roles in AI in drug discovery and 9 in research labs and data, with some roles counted under both.

AI in drug discovery

What the company says: Priority 5

Through our areas of innovation, which include data convergence, artificial intelligence (AI), genetic medicine and genomics, patient-focused disease medicine and therapeutic modalities, we are leveraging powerful tools in order to accelerate discovery

AbbVie 2025 ESG Action Report, No printed date. Its content dates it to 23 Mar 2026 or later, and we read it on 6 Oct 2026, p. 17

AI: We are integrating AI into our R&D processes to support improved drug discovery and development. We use AI to extract knowledge from data across our entire pipeline, from enabling more efficient molecule property prediction

AbbVie 2025 ESG Action Report, No printed date. Its content dates it to 23 Mar 2026 or later, and we read it on 6 Oct 2026, p. 18

Under the terms of the collaboration, Iambic will receive an upfront payment and is eligible to receive success-based milestone payments and tiered royalties on net sales from products generated from the collaboration.

AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery, 21 Sep 2026

the board continues to engage in key topics such as the company’s response to the geopolitical landscape and advances in technology like artificial intelligence

AbbVie 2025 Annual Report (shareholder letters, Form 10-K, 2026 Proxy Statement), Mar 2026, p. 4

What it shows running: Delivery 2, funded or contracted

today announced a multi-year collaboration to accelerate the discovery and development of small molecule therapies with first-in-class and best-in-class potential across immunology, neuroscience and oncology

AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery, 21 Sep 2026

Under the terms of the collaboration, Iambic will receive an upfront payment and is eligible to receive success-based milestone payments and tiered royalties on net sales from products generated from the collaboration.

AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery, 21 Sep 2026

AI: We are integrating AI into our R&D processes to support improved drug discovery and development. We use AI to extract knowledge from data across our entire pipeline, from enabling more efficient molecule property prediction

AbbVie 2025 ESG Action Report, No printed date. Its content dates it to 23 Mar 2026 or later, and we read it on 6 Oct 2026, p. 18

We also use machine learning in multi-omics analysis to help with target identification, preclinical insight and understanding disease pathways

AbbVie 2025 ESG Action Report, No printed date. Its content dates it to 23 Mar 2026 or later, and we read it on 6 Oct 2026, p. 18

The following areas of innovation, including those enabled by AI and machine learning, are allowing us to uncover insights and solutions faster

AbbVie 2025 ESG Action Report, No printed date. Its content dates it to 23 Mar 2026 or later, and we read it on 6 Oct 2026, p. 18

The goal of our collaboration with Iambic is to design better molecules more efficiently and improve our probability of success

AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery, 21 Sep 2026

Commitments made public in the last 12 months: 3

Commitments made public in the year before: 2

Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.

R&D roles open on 6 October 2026: 6

These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.

Technology named in these postings

Named as in use: ARCH (AbbVie R&D Convergence Hub).

A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.

Research labs and data

What the company says: Priority 3

Through our areas of innovation, which include data convergence, artificial intelligence (AI), genetic medicine and genomics, patient-focused disease medicine and therapeutic modalities, we are leveraging powerful tools in order to accelerate discovery

AbbVie 2025 ESG Action Report, No printed date. Its content dates it to 23 Mar 2026 or later, and we read it on 6 Oct 2026, p. 17

Data convergence: We have integrated data across our areas of expertise through technology into a unified knowledge platform, improving how we collect, analyze and apply data to generate insights faster

AbbVie 2025 ESG Action Report, No printed date. Its content dates it to 23 Mar 2026 or later, and we read it on 6 Oct 2026, p. 18

What it shows running: Delivery 4, live

Data convergence: We have integrated data across our areas of expertise through technology into a unified knowledge platform, improving how we collect, analyze and apply data to generate insights faster

AbbVie 2025 ESG Action Report, No printed date. Its content dates it to 23 Mar 2026 or later, and we read it on 6 Oct 2026, p. 18

We are centralizing and connecting data from more than 170 internal and external sources, enabling us to more quickly generate comprehensive insights to inform R&D.

AbbVie 2025 ESG Action Report, No printed date. Its content dates it to 23 Mar 2026 or later, and we read it on 6 Oct 2026, p. 18

Commitments made public in the last 12 months: 0

None identified in the reviewed sources.

Commitments made public in the year before: 0

None identified in the reviewed sources.

Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.

R&D roles open on 6 October 2026: 9

These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.

Technology named in these postings

Named as in use: ARCH (AbbVie R&D Convergence Hub), Posit Connect, Posit Package Manager, Posit Workbench, Slurm, ARCH knowledge graph (R&D Convergence Hub).

Asked for as experience: AWS, Apptainer/Singularity, Mellanox/NVIDIA InfiniBand, NVIDIA GPUs and CUDA.

A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.

Two questions to investigate (Ortent's interpretation)

  1. Lab data and automation roles sit in several AbbVie units, including Biotherapeutics and Genetic Medicine and the team that runs the ARCH data hub. Development Sciences roles are process development and outside this theme. What does each unit own, and who decides on new lab data and automation systems?
  2. AbbVie works on AI in discovery through the Iambic collaboration, an acquisition and federated data consortia, alongside internal computational teams. Who decides whether to join a consortium, license an outside AI platform or build in-house: business development, the AI procurement category or discovery research, and how is it funded?

Coverage limits

AbbVie's main website and investor site blocked access, so its science and venture pages, results slides and call transcripts were not read; only results releases on its news site were. No 10-K text supports any score, because the SEC site refused automated access. Business Wire, several trade sites and parts of PR Newswire were also out of reach, so some partner announcements may be missing. The scores rest on the company press archive, which was screened in full, and the documents that could be read.

// GET IN TOUCH

Clarity when it counts.

For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.

Request a 30-minute intro call